Afatinib was also active in non-small cell lung cancer tumors that harbored certain types of uncommon EGFR mutations, especially Gly719Xaa, Leu861Gln, and Ser768Ile, but less active in other mutations types. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.